{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:14:46Z","timestamp":1793682886405,"version":"4.5.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022714","name":"Fondation de l\u2019UQTR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012589","name":"Fondation Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009850","name":"Universit\u00e9 du Qu\u00e9bec \u00e0 Trois-Rivi\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cjco.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T21:58:04Z","timestamp":1726178284000},"page":"1527-1533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Vanessa's Law on the Reporting of Serious Adverse Events: A Retrospective Study Among Antiplatelet Users in a Tertiary-Care Cardiology Centre"],"prefix":"10.1016","volume":"6","author":[{"given":"Laura Blonde","family":"Guefack Djiokeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Todkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Eve","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"M\u00e9thot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anick","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Midiani","family":"Gonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Raphael","family":"Escobar Gimenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Darveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-2648","authenticated-orcid":false,"given":"Jacinthe","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: an overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.cjco.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s11096-018-0657-1","article-title":"An historical overview over pharmacovigilance","volume":"40","author":"Fornasier","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.cjco.2024.09.003_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40264-016-0444-7","article-title":"Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors","volume":"39","author":"Angamo","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjco.2024.09.003_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bcp.15510","article-title":"Incidence and preventability of hospital admissions for adverse drug reactions in France: a prospective observational study (IATROSTAT)","volume":"89","author":"Laroche","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjco.2024.09.003_bib8","author":"Messier"},{"key":"10.1016\/j.cjco.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1503\/cmaj.202863-f","article-title":"A\u00a0practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes","volume":"194","author":"Alkhalil","year":"2022","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.cjco.2024.09.003_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.revmed.2017.01.013","article-title":"[Management of the bleeding risk associated with antiplatelet agents]","volume":"38","author":"Martin","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.cjco.2024.09.003_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjco.2024.09.003_bib14","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations","volume":"68","author":"Jandoc","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.cjco.2024.09.003_bib18","first-page":"470","article-title":"The MedDRA paradox","author":"Merrill","year":"2008","journal-title":"AMIA Annu Symp Proc 2008"},{"key":"10.1016\/j.cjco.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/2229-3485.184781","article-title":"Reporting of adverse events for marketed drugs: need for strengthening safety database","volume":"7","author":"Apt\u00e9","year":"2016","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.cjco.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.962","article-title":"Under-reporting of serious adverse drug reactions in Sweden","volume":"13","author":"B\u00e4ckstr\u00f6m","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cjco.2024.09.003_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ehjcvp\/pvx038","article-title":"Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System","volume":"4","author":"Cherepanov","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2024.09.003_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5414\/CP203365","article-title":"Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system","volume":"57","author":"Fahmy","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cjco.2024.09.003_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/DHPS.S31103","article-title":"Awareness among nurses about reporting of adverse drug reactions in Sweden","volume":"4","author":"Ekman","year":"2012","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.cjco.2024.09.003_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0253-7613.150344","article-title":"Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India","volume":"47","author":"Tandon","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.cjco.2024.09.003_bib28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/healthcare10061015","article-title":"Under-reporting of adverse drug reactions in Finland and healthcare professionals' perspectives on how to improve reporting","volume":"10","author":"Sandberg","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.cjco.2024.09.003_bib29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2165\/00002018-200730110-00006","article-title":"Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region","volume":"30","author":"Irujo","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjco.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/14740338.2020.1849137","article-title":"Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system","volume":"20","author":"Monteiro","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjco.2024.09.003_bib31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2515\/therapie\/2012059","article-title":"Adverse drug reactions in older adults: a retrospective study from pharmacovigilance","volume":"67","author":"Charfi","year":"2012","journal-title":"Therapie"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24003834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24003834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T05:02:34Z","timestamp":1733374954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X24003834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2589790X24003834"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2024.09.003","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Vanessa's Law on the Reporting of Serious Adverse Events: A Retrospective Study Among Antiplatelet Users in a Tertiary-Care Cardiology Centre","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}